Trinity Biotech Plc ADR (NASDAQ:TRIB) does about 62.05K shares in volume on a normal day but saw 3004122 shares change hands in the recent trading day. The company now has a market cap of 15.51M USD. Its current market price is $2.03, marking an increase of 1.50% compared to the previous close of $2.00. The 52 week high reached by this stock is $4.59 whilst the lowest price level in 52 weeks is $1.49.
Trinity Biotech Plc ADR (TRIB) has a 20-day trading average at $2.54 and the current price is -55.75% off the 52-week high compared with 36.24% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.59 and its 200-day simple moving average is $2.26. If we look at the stock’s price movements over the week, volatility stands at 8.55%, which increases to 12.15% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 36.15 to suggest the stock is neutral.
The consensus objective for the share price is $15.00, suggesting that the stock has a potential upside of 86.47% over the period.
ROTH Capital reiterated its price target at $22-$20.
The current price level is -21.10%, -22.45%, and -10.15% away from its SMA20, SMA50, and SMA200 respectively, with the TRIB price moving above the 50-day SMA on current market day. Trinity Biotech Plc ADR (TRIB) stock is down -14.96% over the week and -29.02% over the past month. Its price is -5.36% year-to-date and -43.69% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -1.32 below consensus estimates by -1.02. The company’s next earnings report forecasts estimating quarterly EPS at -0.55 and -2.15 for whole year. Expected sales for next quarter are $17M, which analysts say will come at $63.55M for the current fiscal year and next year at $71M. In addition, estimates put the company’s current quarterly revenue at an average of $16M.
To reach the target analysts have set, the stock logically needs to grow 86.47 percent from here.
Outstanding shares total 7.67M with insiders holding 23.64% of the shares and institutional holders owning 28.58% of the company’s common stock. The company has a return on investment of -36.21% and return on equity of -1967.61%. The beta has a value of 1.22. Price to sales ratio is 0.26.
